The structure of morbidity and the risk of oncological pathology in patients with chronic kidney disease using the example of the population of Saint Petersburg
https://doi.org/10.24884/1607-4181-2025-32-3-61-67
Abstract
Introduction. Cancer patients with chronic kidney disease stage 5 on dialysis (CKD 5D) constitute a separate, complex group of patients. Conducting diagnostics and specialized oncological treatment for such patients is often associated with a number of difficulties and risks. However, there is still no data on the incidence and predominant localization of malignant tumors in patients with CKD in the Russian population.
The objective was to determine the frequency of detection of solid oncopathology in people with CKD 5D using the example of the population of St. Petersburg.
Methods and materials. In 2019, the population of Saint Petersburg was 532,890 people. The number of new cases of solid malignant neoplasms (MNP) of diseases in 2019 amounted to 20,028 people. The number of patients registered on 31.12.2018 in the nephrological registry of Saint Petersburg was 2,958 people with CKD 5D.
Results. When comparing the databases with the first oncopathology in 2019 and the database of nephrological patients in Saint Petersburg, it was revealed that solid MNP were diagnosed in 37 patients suffering from CKD 5D. Most often, the localization of solid MNP with CKD 5D patients were: lung, stomach, prostate, and uterine cancers.
Conclusions. The risk of developing solid MNP in patients with ESRD was significantly higher – the odds ratio (OR) was 3.353.
Keywords
Supporting agencies: The authors express their gratitude in the text editing and advisory work with the material to the Head of the Department of Medical Statistics of Tumor Diseases of the Saint Petersburg State Budgetary Healthcare Institution “Medical Information and Analytical Center” – Khizhe Valentin Vasilievich and Zemchenkov Aleksandr Iurievich – the Chief Freelance Specialist-Nephrologist of Saint Petersburg in 2019.
About the Authors
I. A. Paltyshev
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Paltyshev Ilya A., Cand. of Sci. (Med), Oncologist of the Oncological Department № 1, Head of the Department of Pediatric Surgery, Research Institute of Surgery and Emergency Medicine, Associate Professor of the Department of Oncology of the Faculty of Postgraduate Education
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
M. A. Belyaev
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Belyaev Mikhail A., Cand. of Sci. (Med), Research Fellow, Head of the Department of Abdominal Oncology, Deputy Chief Physician of Oncology Clinics
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
K. N. Vovin
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Vovin Kirill N., Cand. of Sci. (Med), Oncologist, Surgeon of the Oncological Department № 1, Research Institute of Surgery and Emergency Medicine, Associate Professor of the Department of Oncology of the Faculty of Postgraduate Education
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
A. A. Zakharenko
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Zakharenko Aleksandr A., Dr. of Sci. (Med), Professor, Head of the Department of Oncology of the Faculty of Postgraduate Education
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
S. F. Bagnenko
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Bagnenko Sergey F., Dr. of Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Rector
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
References
1. Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492.).
2. Shakhzadova A.O., Starinsky V.V., Lisichnikova I.V. Cancer care to the population of Russia in 2022. Siberian journal of oncology. 2023;22(5):5-13. (In Russ.) https://doi.org/10.21294/1814-4861-2023-22-5-5-13 (In Rus).
3. Lv JC, Zhang LX. Prevalence and Disease Burden of Chronic Kidney Disease. Adv Exp Med Biol. 2019; 1165:3-15. doi: 10.1007/978-981-13-8871-2_1. PMID: 31399958.
4. Rumyantseva EI. Chronic kidney disease as a global public health problem: trends in morbidity and mortality. Health Care Standardization Problems. 2021; 1-2: 41-49. DOI: 10.26347/1607-2502202101-02041-049(In Rus).
5. Hu, M.; Wang, Q.; Liu, B.; Ma, Q.; Zhang, T.; Huang, T.; Lv, Z.; Wang, R. Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms. Front. Cell Dev. Biol. 2022, 10, 868715.
6. Ciorcan, M.; Chisavu, L.; Mihaescu, A.; Gadalean, F.; Bob, F.R.; Negru, S.; Schiller, O.M.; Grosu, I.D.; Marc, L.; Chisavu, F.; et al. chronic kidney disease in cancer patients, the analysis of a large oncology database from Eastern Europe. PLoS ONE 2022, 17, e0265930.
7. Plaisier, E.; Ronco, P. Screening for Cancer in Patients with Glomerular Diseases. Clin. J. Am. Soc. Nephrol. 2020, 15, 886–888.
8. Yarandi N, Shirali AC. Onconephrology: Core Curriculum 2023. Am J Kidney Dis. 2023 Dec;82(6):743-761. doi: 10.1053/j.ajkd.2023.04.014. Epub 2023 Oct 17. PMID: 37855786.
9. Lees JS, Elyan BMP, Herrmann SM, Lang NN, Jones RJ, Mark PB. The 'other' big complication: how chronic kidney disease impacts on cancer risks and outcomes. Nephrol Dial Transplant. 2023 May 4;38(5):1071-1079. doi: 10.1093/ndt/gfac011. PMID: 35090037; PMCID: PMC10157781.
10. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS. Increased incidence of malignancy during chronic renal failure. Lancet. 1975 Apr 19;1(7912):883-6. doi: 10.1016/s0140-6736(75)91684-0. PMID: 47534.
11. Janus, N., Launay-Vacher, V., Thyss, A., et al. (2013). Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Annals of oncology: official journal of the European Society for Medical Oncology, 24(2), 501–507. https://doi.org/10.1093/annonc/mds344.
12. Lee, J. E., Han, S. H., Cho, B. C., et al. (2009). Cancer in patients on chronic dialysis in Korea. Journal of Korean medical science, 24 Suppl (Suppl 1), S95–S101. https://doi.org/10.3346/jkms.2009.24.S1.S95.
13. Park, S., Lee, S., Kim, Y., et al. (2019). Risk of cancer in pre-dialysis chronic kidney disease: A nationwide population-based study with a matched control group. Kidney research and clinical practice, 38(1), 60–70. https://doi.org/10.23876/j.krcp.18.0131.
14. Oh, H. J., Lee, H. A., Moon, C. et al. (2020). The Combined Impact of Chronic Kidney Disease and Diabetes on the Risk of Colorectal Cancer Depends on Sex: A Nationwide Population-Based Study. Yonsei medical journal, 61(6), 506–514. https://doi.org/10.3349/ymj.2020.61.6.506.
15. Oh HJ, Lee HA, Moon CM, Ryu DR. Incidence risk of various types of digestive cancers in patients with pre-dialytic chronic kidney disease: A nationwide population-based cohort study. PLoS One. 2018 Nov 20;13(11):e0207756. doi: 10.1371/journal.pone.0207756. PMID: 30458033; PMCID: PMC6245741.
16. Lee YC, Hung SY, Wang HK, Lin CW, Wang HH, Chang MY, Sung JM, Chiou YY, Lin SH. Is there different risk of cancer among end-stage renal disease patients undergoing hemodialysis and peritoneal dialysis? Cancer Med. 2018 Feb;7(2):485-498. doi: 10.1002/cam4.1289. Epub 2018 Jan 22. PMID: 29356425; PMCID: PMC5806101.
17. Suprunovich K.S., Paltyshev I.A., Zakharenko A.A., et al. Onconephrology: acute kidney disease after preventive ileostomy in a patient with colorectal cancer. Nephrology (Saint-Petersburg). 2023;27(1):102-107. (In Russ.) https://doi.org/10.36485/1561-6274-2023-27-1-102-107(In Rus).
18. Yesayan A.M., Al-Shukri S., Mosoyan M.S. Renal cell carcinoma and chronic kidney disease: attention to distant non-oncologic results. Nephrology (Saint-Petersburg). 2012;16(4):94-99. (In Russ.) https://doi.org/10.24884/1561-6274-2012-16-4-94-99 (In Rus).
19. Kovalenko N.V., Ivanov A.I., Galeev S.R. et al. Surgical Treatment of Gastric Malignancy in Chronic Kidney Disease Patient with Long-Term Haemodialysis. Creative surgery and oncology. 2021;11(4):337-342. (In Russ.) https://doi.org/10.24060/2076-3093-2021-11-4-337-342(In Rus).
Review
For citations:
Paltyshev I.A., Belyaev M.A., Vovin K.N., Zakharenko A.A., Bagnenko S.F. The structure of morbidity and the risk of oncological pathology in patients with chronic kidney disease using the example of the population of Saint Petersburg. The Scientific Notes of the Pavlov University. 2025;32(3):61-67. (In Russ.) https://doi.org/10.24884/1607-4181-2025-32-3-61-67
Views:
40
Email this article 